1-3 of 3
Evan M. Braunstein
Close
Sort by
Journal Articles

C5 inhibition allows continued antineoplastic therapy in cancer- and chemotherapy-associated thrombotic microangiopathy

Clinical Trials & Observations
Hridaya Shah, Hang Chen, Xiang-Zuo Pan, Ara Metjian, Robert A. Brodsky, Evan M. Braunstein, Shruti Chaturvedi
Journal: Blood Advances
Blood Adv (2022) 6 (23): 6071–6074.
https://doi.org/10.1182/bloodadvances.2022008395
Published: 2022
Includes: Supplemental data
Journal Articles

Outcomes of a clinician-directed protocol for discontinuation of complement inhibition therapy in atypical hemolytic uremic syndrome

Clinical Trials & Observations
Shruti Chaturvedi, Noor Dhaliwal, Sarah Hussain, Kathryn Dane, Harshvardhan Upreti, Evan M. Braunstein, Xuan Yuan, C. John Sperati, Alison R. Moliterno, Robert A. Brodsky
Journal: Blood Advances
Blood Adv (2021) 5 (5): 1504–1512.
https://doi.org/10.1182/bloodadvances.2020003175
Published: 2021
Journal Articles

Sex determines the presentation and outcomes in MPN and is related to sex-specific differences in the mutational burden

Clinical Trials & Observations
Theodoros Karantanos, Shruti Chaturvedi, Evan M. Braunstein, Jerry Spivak, Linda Resar, Styliani Karanika, Donna M. Williams, Ophelia Rogers, Christopher D. Gocke, Alison R. Moliterno
Journal: Blood Advances
Blood Adv (2020) 4 (12): 2567–2576.
https://doi.org/10.1182/bloodadvances.2019001407
Published: 2020
Includes: Supplemental data